Novel Quinoxaline-2-Carbonitrile-1,4-Dioxide Derivatives Suppress HIF1α Activity and Circumvent MDR in Cancer Cells

Overcoming drug resistance by cell-penetrating peptide-mediated delivery of a doxorubicin dimer with high DNA-binding affinity

(2017) Marco Lelle et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Mechanism Underlying the Reversal of Drug Resistance in P-Glycoprotein-Expressing Leukemia Cells by Pinoresinol and the Study of a Derivative

(2017) María L. González et al.   Frontiers in Pharmacology

Quinoxaline Nucleus: A Promising Scaffold in Anti-cancer Drug Discovery

(2016) Alessandra C. Pinheiro et al.   Anti-Cancer Agents in Medicinal Chemistry

Targeting HIF-1α is a prerequisite for cell sensitivity to dichloroacetate (DCA) and metformin

(2016) Sung-Eun Hong et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Synthesis and biological evaluation of quinoxaline di- N -oxide derivatives with in vitro trypanocidal activity

(2016) Silvia Pérez-Silanes et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Hypoxia: A Double-Edged Sword in Cancer Therapy

(2016) Hamed Manoochehri Khoshinani et al.   CANCER INVESTIGATION

Access to steroidal pyridazines via modified thiohydrazides

(2016) Y. A. Volkova et al.   RSC Advances

Quinoxaline 1,4-di-N-Oxides: Biological Activities and Mechanisms of Actions

(2016) Guyue Cheng et al.   Frontiers in Pharmacology

Exploring the HIFs, buts and maybes of hypoxia signalling in disease: lessons from zebrafish models

(2015) P. M. Elks et al.   Disease Models & Mechanisms

Recent Advances in Design of Potential Quinoxaline Anti-Infectives

(2014) Josef Jampilek   CURRENT MEDICINAL CHEMISTRY

Snail/beta-catenin signaling protects breast cancer cells from hypoxia attack

(2013) Alexander M. Scherbakov et al.   EXPERIMENTAL CELL RESEARCH

New Insight into P-Glycoprotein as a Drug Target

(2012) Albert Breier et al.   Anti-Cancer Agents in Medicinal Chemistry

Synthesis and Biological Evaluation of 3-Aryl-quinoxaline-2-carbonitrile 1,4-Di-N-oxide Derivatives as Hypoxic Selective Anti-tumor Agents

(2012) Yunzhen Hu et al.   MOLECULES

New salicylamide and sulfonamide derivatives of quinoxaline 1,4-di-N-oxide with antileishmanial and antimalarial activities

(2011) Carlos Barea et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Synthesis and Biological Evaluation of New Quinoxaline Derivatives as Antioxidant and Anti-Inflammatory Agents

(2011) Asunción Burguete et al.   Chemical Biology & Drug Design

New quinoxaline 1, 4-di-N-oxides: Anticancer and hypoxia-selective therapeutic agents

(2010) Magda M.F. Ismail et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group

(2010) Danny Rischin et al.   JOURNAL OF CLINICAL ONCOLOGY

Doxorubicin pathways

(2010) Caroline F. Thorn et al.   Pharmacogenetics and Genomics

Suppression of Hypoxia-Inducible Factor 1α (HIF-1α) by Tirapazamine Is Dependent on eIF2α Phosphorylation Rather Than the mTORC1/4E-BP1 Pathway

(2010) Jun Zhang et al.   PLoS One

The breast cancer cells response to chronic hypoxia involves the opposite regulation of NF-kB and estrogen receptor signaling

(2009) Alexander M. Scherbakov et al.   STEROIDS

Tirapazamine: a novel agent targeting hypoxic tumor cells

(2008) Srini B Reddy et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Cell lysis with dimethyl sulphoxide produces stable homogeneous solutions in the dichlorofluorescein oxidative stress assay

(2008) Guqi Wang et al.   FREE RADICAL RESEARCH